ARTICLE | Company News
Gilead gets rights to NASH candidates from Yuhan
January 7, 2019 3:04 AM UTC
Continuing to grow its fibrosis pipeline, Gilead Sciences Inc. (NASDAQ:GILD) licensed ex-Korean rights from Yuhan Corp. (KSE:000100) to develop small molecules against two undisclosed targets to treat advanced fibrosis due to non-alcoholic steatohepatitis.
The deal comes less than a month after Gilead acquired options to license TGFβ1 programs for fibrosis indications from Scholar Rock Holding Corp. (NASDAQ:SRRK) (see "Gilead Grows Fibrosis Pipeline with Scholar Rock Deal")...